# This Page Is Inserted by IFW Operations and is not a part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/646,835	01/11/2001	Gabriele Multhoff	40740	1173
	7590 08/05/2002	İ		
•	rams Berdo & Goodn	nan	EXAMINER	
Suite 600 1300 19th Street NW Washington, DC 20036		; (	CANELLA, KAREN A	
			ART UNIT	PAPER NUMBER
		I	1642	110
			DATE MAILED: 08/05/2002	14

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. 09/646,835 Applicant(s)

Examiner

Art Unit

Multhoff

Karen Canella 1642 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 30 days MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the

mailing date of this communication.  If the period for reply specified above is less than thirty (30) days, a reply.  If NO period for reply is specified above, the maximum statutory period v.  Failure to reply within the set or extended period for reply will, by statute.  Any reply received by the Office later than three months after the mailing earned patent term edjustment. See 37 CFR 1.704(b).	within the statutory minimum of thirty (30) days will be considered timely.  vill apply and will expire SIX (6) MONTHS from the mailing date of this communication.  cause the application to become ABANDONED (35 U.S.C. § 133).  date of this communication, even if timely filed, may reduce any
Status	
1) Responsive to communication(s) filed on	
2a) ☐ This action is FINAL. 2b) ☑ T	his action is non-final.
	vance except for formal matters, prosecution as to the merits is *Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposition of Claims	•
4) 💢 Claim(s) <u>31-60</u>	is/are pending in the application.
4a) Of the above, claim(s)	is/are withdrawn from consideration.
5) Claim(s)	is/are allowed.
6) Claim(s)	is/are rejected.
7)	is/are objected to.
8) 💢 Claims <u>31-60</u>	are subject to restriction and/or election requirement.
Application Papers	
9) The specification is objected to by the Exam	iner.
10) The drawing(s) filed on	is/are a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection t	o the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
11) The proposed drawing correction filed on	is: a)□ approved b)□ disapproved by the Examiner
If approved, corrected drawings are required in	
12) The oath or declaration is objected to by the	Examiner.
Priority under 35 U.S.C. §§ 119 and 120	
13) Acknowledgement is made of a claim for for	eign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) $\square$ All b) $\square$ Some* c) $\square$ None of:	
<ol> <li>Certified copies of the priority documer</li> </ol>	nts have been received.
2. Certified copies of the priority documer	nts have been received in Application No
application from the Internation	
*See the attached detailed Office action for a lis	
14) Acknowledgement is made of a claim for do	
a) Li The translation of the foreign language pro	···
15) Acknowledgement is made of a claim for do Attachment(s)	mestic priority under 30 0.5.C. 33 120 and/or 121.
1) Notice of References Cited (PTC-892)	4) Interview Summary (PTO-413) Paper No(s).
Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Cther:

#### DETAILED ACTION

Claims 1-30 have been canceled. Claims 31-60 have been added. Upon review of the newly submitted claims the restriction requirement of Paper No. 14, mailed March 27, 2002 has been withdrawn.

#### Election/Restrictions

 This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

- a. cancerous diseases,
- b. autoimmune diseases, and
- c. infectious diseases.

Applicant is required, in reply to this action, to elect a single species, a, b or c, to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after

Application/Control Number: 09/646,835

Art Unit: 1642

the election, applicant must indicate which are readable upon the elected species. MPEP  $\S$  809.02(a).

2. The claims are deemed to correspond to the species listed above in the following manner:

Claims 31-41 and 54: species of groups a and c.

Claims 42-49 and 55-60: species of groups a, b and c.

The following claim(s) are generic: 31-47 and 50-60.

3. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

The diseases of tumors, solid tumors, leukemia and lymphomas and autoimmune diseases are linked with the common technical feature of being disorders arising from the failure of the immune system to recognize endogenous tissues expressing self-antigens which become autonomous within the confines of the organism.

The diseases of autoimmunity are linked with the common technical feature of the failure of the immune system to recognize normal self antigens as toleragens.

The diseases of bacterial, viral or mycotic infection are linked with the common technical feature of the failure of the immune system to recognize non-self antigens within endogenous tissues.

Application/Control Number: 09/646,835

Art Unit: 1642

4. Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Karen Canella whose telephone number is (703) 308-8362. The examiner

can normally be reached on Monday through Friday from 8:30 am to 6:00 pm. A message may

be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are

unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995.

Any inquiry of a general nature or relating to the status of this application or proceeding should

be directed to the Group receptionist whose telephone number is (703) 308-0196.

Patent Examiner, Group 1642

August 1, 2002

Page 4